Can We Omit Auto-SCT in Patients With Mantle Cell Lymphoma With Undetectable...
Autologous hematopoietic stem cell transplantation (auto-SCT) did not improve the outcomes of patients with mantle cell lymphoma who had undetectable minimal residual disease (MRD) after induction...
View ArticleInMIND: Novel Standard of Care for Relapsed or Refractory Follicular Lymphoma?
A treatment regimen of tafasitamab plus lenalidomide and rituximab outperformed lenalidomide plus rituximab and a placebo in patients with relapsed or refractory follicular lymphoma in a phase 3 study,...
View ArticleCognitive and Neural Network Changes Post-Chemotherapy Treatment
The following is a summary of “Chemotherapy-Related Cognitive Impairment and Changes in Neural Network Dynamics: A Systematic Review,” published in the December 2024 issue of Neurology by Leskinen et...
View ArticleBayesian Analysis of Protein Delivery and Mortality in Critical Care
The following is a summary of “Higher Versus Lower Protein Delivery in Critically Ill Patients: A Systematic Review and Bayesian Meta-Analysis,” published in the December 2024 issue of Critical Care by...
View ArticleCharacterization of Immune Cell Dynamics in Psoriasis Lesions
The following is a summary of “FC02 Immune cell signatures and T-cell receptor profiling reveal pathogenetic mechanisms in psoriasis,” published in the December 2024 issue of Dermatology by Deng et al....
View ArticleIncreased Biosignal Entropy Associated with Poor TBI Outcomes
The following is a summary of “Dynamic assessment of signal entropy for prognostication and secondary brain insult detection after traumatic brain injury,” published in the December 2024 issue of...
View ArticleRole of MRSA Nares PCR in De-escalating Antibiotics in ICU
The following is a summary of “Utility of MRSA nares PCR for non-respiratory cultures in critically ill patients: an observational evaluation,” published in the December 2024 issue of Infectious...
View ArticleCombining Triage and Frailty for Better ED Mortality Outcomes
The following is a summary of “Evaluating the Prognostic Value of Adding Frailty to Triage Assessment in Elderly Patients with Lower Acuity Presentations in the Emergency Department,” published in the...
View ArticleGp05 Modulates MRSA Persistence by Altering Cell Surface Charge
The following is a summary of “Phage-Encoded Virulence Factor, Gp05, Alters Membrane Phospholipids and Reduces Antimicrobial Susceptibility in Methicillin-Resistant Staphylococcus aureus,” published in...
View ArticleIdentifying Gaps in Pain Medicine Fellowship Training and Education
The following is a summary of “Employer Perspective on Pain Fellowship Education: A Survey to Understand the Current State of Pain Medicine Training,” published in the December 2024 issue of Pain by...
View ArticleAnalyzing Systemic Adverse Drug Events of Prostaglandin Analogs in Glaucoma
The following is a summary of “Systemic adverse drug events to topical prostaglandin analogs for treating glaucoma: a retrospective focused pharmacovigilance study,” published in the December 2024...
View ArticleUltrasound Prognostic Value for Predicting COVID-19 Hospitalization and ICU...
The following is a summary of “Clinical and ultrasound characteristics in patients with sars-cov-2 pneumonia, associated with hospitalization prognosis. e-covid project,” published in the December 2024...
View ArticleSuccess With Adjuvant Ribociclib Leads to FDA Approval in Early Breast Cancer
Adjuvant ribociclib, a CDK4/6 inhibitor, combined with an aromatase inhibitor significantly improved invasive disease-free survival (iDFS) at 3 years in patients with HR-positive/HER2-negative early...
View ArticleNeoadjuvant HER3-DXd Achieves pCR & ORR Results Similar to Multi-Agent...
Neoadjuvant patritumab deruxtecan (HER3-DXd) alone or with letrozole achieved similar pathologic complete response (pCR) rate and overall response rate (ORR) estimates compared with multi-agent...
View ArticleInavolisib FDA-Approved for Triplet Combination Use for Metastatic Breast Cancer
Inavolisib, in combination with palbociclib and fulvestrant, met its primary endpoint of progression-free survival (PFS) in patients with PIK3CA-mutated, HR-positive/HER2-negative metastatic breast...
View ArticleImproved TFF & PFS Seen With Palbociclib Plus ET in Real-World PADMA Study
The real-world, phase 4 PADMA study showed a significant and clinically meaningful improvement in time-to-treatment failure (TTF) and progression-free survival (PFS) with palbociclib plus endocrine...
View ArticleMargetuximab Does Not Improve pCR Rate in HER2-Positive Early Breast Cancer
The MARGOT/TBCRC052 trial failed to show a significant improvement in pathologic complete response (pCR) rates with margetuximab compared with trastuzumab in patients with early-stage HER2-positive...
View ArticleImlunestrant Improves PFS in ESR1-Mutated ER-Positive/HER2-Negative Advanced BC
The EMBER-3 trial demonstrated the effectiveness of imlunestrant, both as monotherapy and in combination with abemaciclib, in patients with ESR1-mutated oestrogen (ER)-positive/HER2-negative advanced...
View ArticleNeoadjuvant SHR-A1811 Shows Promise in Fighting HER2-Positive Breast Cancer
In the phase 2 FASCINATE-N trial, neoadjuvant SHR-A1811 showed similar pathologic complete response (pCR) rates to the standard 4-drug regimen, with a tolerable safety profile in patients with...
View ArticleOlaparib Shows Long-Term Benefit in High-Risk BRCA1/2-Mutated Breast Cancer
After a median follow-up of 6.1 years, olaparib continued to demonstrate improved invasive disease-free survival (IDFS), distant disease-free survival (DDFS), and overall survival (OS) in patients with...
View Article